Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Capital Expenditures: 2023-2025

Historic Capital Expenditures for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to $98,000.

  • Contineum Therapeutics' Capital Expenditures rose 19.51% to $98,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $355,000, marking a year-over-year decrease of 45.97%. This contributed to the annual value of $514,000 for FY2024, which is 24.15% up from last year.
  • Contineum Therapeutics' Capital Expenditures amounted to $98,000 in Q3 2025, which was up 122.73% from $44,000 recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Capital Expenditures registered a high of $309,000 during Q4 2023, and its lowest value of $22,000 during Q3 2023.
  • Its 3-year average for Capital Expenditures is $101,545, with a median of $82,000 in 2024.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 283.87% in 2024, then slumped by 68.03% in 2025.
  • Over the past 3 years, Contineum Therapeutics' Capital Expenditures (Quarterly) stood at $309,000 in 2023, then plummeted by 46.28% to $166,000 in 2024, then rose by 19.51% to $98,000 in 2025.
  • Its Capital Expenditures stands at $98,000 for Q3 2025, versus $44,000 for Q2 2025 and $47,000 for Q1 2025.